Quest LaboratoriesShare price, financial results, shareholding and management
- Market cap
- ₹146 cr
- Stock P/E
- 9.7peers 19.8
- Book value
- ₹59.1
- Price to book
- 1.51
- EV / operating profit
- 8.4
- Market cap to sales
- 1.31
- ROCE · FY26
- 18.4%
- ROE · FY26
- 16.8%
- ROE, 3-year average
- 28.9%
- Operating margin · FY26
- 16.3%peers 12.8%
- Sales growth, 3 years
- 21.7%
- Profit growth, 3 years
- 44.3%
- Debt to equity
- 0.08peers 0.48
- Borrowings
- ₹7.9 cr
- Interest cover
- 10.8×
- Cash from business / op. profit
- -59%
- Debtor days
- 118
- Pledged
- 0.00%
- Promoter holding
- 66.78%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 911
- 52-week high / low
- ₹153 / ₹69
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Quest Laboratories share price chart
Close on 18 Nov 2026 · +0.06% on the day · Vol 2,400
Daily prices to 18 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 18 Nov 2026
- 1 month
- -1.2%
- 3 months
- +0.1%
- 6 months
- -18.0%
- 1 year
- +0.9%
- Since IPO
- -8.1%
- Traded a day, 20 days
- ₹0.10 cr
- Taken for delivery
- 86%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +8% | +11% |
| 3 years, a year | +22% | +44% |
| Latest half, H2 FY26 | +3% | +24% |
About Quest Laboratories: business, products and customers
Quest Laboratories makes everyday generic medicines such as tablets, syrups, oral rehydration salts and ointments at its plant in Pithampur, Madhya Pradesh, mostly for government health programmes. Its shares trade on NSE Emerge.
Quest Laboratories has one factory at Pithampur near Indore, where it makes several hundred generic formulations: antibiotics, painkillers, antimalarials, diabetes and allergy medicines, vitamins, oral rehydration salts, creams and antiseptic liquids. Tablets bring in most of the money. It reaches buyers in four ways: bids in state and central government tenders for medicines given out free, a franchise model where regional partners market its products, white label manufacturing for other drug companies, and exports through buyers abroad.
Government tenders give bulk orders and fixed volumes, but the price is set by bidding, so margins rest on keeping costs low. Government buyers are also slow payers, and the company holds large stocks of medicines and materials, so a big part of its money sits in receivables and inventory. The plant runs close to full on syrups, tablets and oral salts, while dry syrups and external liquids are used far less.
Read more about the business
The offer document compares it with Beta Drugs, Alpa Laboratories and Zenith Drugs, other listed makers of generic formulations. The company is building an injectable section for vials, ampoules and dry injections, aimed at cancer medicines and export markets, and is setting up a capsule line. In September 2026 it began an advisory tie up with Niraga Capitals to look at export markets, partnerships, fund raising and acquisitions.
From the offer document, the FY26 annual report, the July 2025 investor presentation and the company's September 2026 exchange announcements.
Read the deeper study ↓In its favour
- Sales have grown fast: 22% a year over three years.
- It has little debt for its size: debt to equity 0.08.
- The promoters own a large part of the company: 66.78%.
To watch
- Delivery of the ₹39.7 cr order book, including ₹10.7 cr of export orders for the third quarter of FY27 (Exchange announcement, 28 Sep 2026).
- Completion of the injectable section for vials, ampoules and dry injections (Investor presentation, Jul 2025, p.4).
- Whether the large stock built up at March 2026 turns into sales and cash (Annual report FY26, p.55).
- Any fund raising, partnership or acquisition that comes out of the Niraga Capitals advisory tie up (Exchange announcement, 28 Sep 2026).
- It paid no dividend in the past year.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Quest Laboratories revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew roughly in step with sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Quest Laboratories half-yearly results
SME companies report every six months · ₹ crore
| H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|
| Sales | 61.29 | 48.80 | 63.02 |
| Expenses | 56.67 | 41.61 | 51.97 |
| Operating profit | 4.62 | 7.20 | 11.05 |
| OPM | 7.5% | 14.8% | 17.5% |
| Interest | 0.40 | 1.22 | 0.63 |
| Depreciation | 0.34 | 0.41 | 0.41 |
| Profit before tax | 7.29 | 8.84 | 9.27 |
| Net profit | 5.56 | 8.12 | 6.90 |
Quest Laboratories profit and loss
Full years to March, FY21 to FY26 · ₹ crore, consolidated where reported
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Sales | 30 | 59 | 62 | 83 | 103.91 | 111.82 |
| Expenses | 29 | 53 | 54 | 67 | 87.93 | 93.58 |
| Operating profit | 1 | 6 | 8 | 16 | 15.98 | 18.24 |
| OPM | 4.7% | 11.0% | 13.0% | 19.0% | 15.4% | 16.3% |
| Other income | 0 | 0 | 0 | 0 | 4.24 | 2.54 |
| Interest | 0 | 0 | 1 | 1 | 0.91 | 1.85 |
| Depreciation | 0 | 0 | 1 | 1 | 0.64 | 0.82 |
| Exceptional and other items | · | · | 1 | · | · | · |
| Profit before tax | 1 | 6 | 7 | 14 | 18.68 | 18.11 |
| Tax rate | 0.0% | 33.3% | 28.6% | 28.6% | 27.4% | 17.1% |
| Net profit | 1 | 4 | 5 | 10 | 13.57 | 15.02 |
| EPS ₹ | · | · | · | 8.45 | 8.28 | 9.16 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
The years to FY24 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Quest Laboratories profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Operating margin | 4.7% | 11.0% | 13.0% | 19.0% | 15.4% | 16.3% |
| Tax rate | 0.0% | 33.3% | 28.6% | 28.6% | 27.4% | 17.1% |
| ROCE | · | 54.5% | 50.0% | 56.6% | 26.8% | 18.4% |
| ROE | · | 50.0% | 40.0% | 45.5% | 24.5% | 16.8% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Quest Laboratories debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business used more cash than it brought in. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Quest Laboratories balance sheet
At each 31 March · ₹ crore
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 12 | 16.39 | 16.39 |
| Reserves | 5 | 9 | 14 | 17 | 65.42 | 80.43 |
| Net worth | 6 | 10 | 15 | 29 | 81.80 | 96.82 |
| Borrowings | 3 | 3 | 4 | 5 | 30.25 | 7.89 |
| Other liabilities | 9 | 22 | 28 | 27 | 9.60 | 6.44 |
| Total liabilities | 18 | 35 | 47 | 61 | 121.65 | 111.15 |
| Fixed assets | 6 | 7 | 10 | 10 | 11.79 | 14.81 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 1.46 |
| Investments | 0 | 0 | 0 | 7 | 49.23 | 12.18 |
| Other assets | 12 | 28 | 37 | 44 | 60.63 | 82.70 |
| Receivables | · | · | · | · | 30.03 | 36.21 |
| Inventory | · | · | · | · | 21.37 | 38.62 |
| Cash | · | · | · | · | 0.11 | 0.10 |
| Trade payables | · | · | · | · | 5.73 | 5.61 |
Quest Laboratories cash flow
₹ crore
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Cash from operations | 1 | 3 | 4 | 3 | -23.48 | -10.72 |
| Cash from investing | -1 | -2 | -4 | -5 | -43.97 | 34.94 |
| Cash from financing | 0 | 0 | 0 | 2 | 67.42 | -24.23 |
| Net cash flow | 0 | 1 | 0 | 0 | -0.03 | -0.01 |
| Capital spending | · | · | · | · | 3.47 | 5.25 |
Working capital
Days
| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Debtor days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash conversion cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working capital days | 9 | 14 | 27 | 58 | 72 | 218 |
Quest Laboratories peers and competitors
Listed SME companies in the same industryBy sales, Quest Laboratories is number 13 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 146 | 9.7 | 112 | 15 | 16.3% | 0.08 |
| KRM Ayurveda | 573 | 28.6 | 102 | 20 | 30.0% | 0.00 |
| Sotac Pharmaceuticals | 100 | 17.3 | 101 | 5.8 | 17.7% | 0.64 |
| Accretion Pharmaceuticals | 215 | 22.2 | 89.6 | 9.7 | 16.7% | 0.23 |
| Walpar Nutritions | 25 | 9.9 | 78.8 | 2.5 | 8.5% | 0.89 |
| Median of the 10 others | 158 | 19.8 | 123 | 6.1 | 12.8% | 0.48 |
Quest Laboratories shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little more than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has come down.
Quest Laboratories shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| May 24 | Sep 24 | Dec 24 | Mar 25 | Sep 25 | Dec 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|
| Promoters | 65.83% | 65.83% | 65.83% | 66.21% | 66.78% | 66.78% | 66.78% |
| Foreign investors (FIIs) | 4.60% | 0.74% | 1.31% | 0.95% | 0.93% | 0.61% | 0.61% |
| Indian institutions (DIIs) | 7.10% | 4.44% | 4.86% | 2.07% | 1.39% | 1.37% | 2.04% |
| HNIs (over ₹2 lakh each) | 6.73% | 13.22% | 11.54% | 12.09% | 11.95% | 15.32% | 15.48% |
| Small holders (up to ₹2 lakh) | 11.87% | 9.90% | 10.56% | 12.26% | 13.55% | 13.04% | 11.51% |
| Companies and others | 3.87% | 5.87% | 5.90% | 6.42% | 5.40% | 2.88% | 3.58% |
| Number of shareholders | 1,732 | 857 | 897 | 1,001 | 1,084 | 1,017 | 911 |
The named holders are at 31 March 2026, beside 31 Dec 2025, each under the group the pattern files them in.
Quest Laboratories study: the business from its own documents
Read from 7 of the company's own documentsQuest Laboratories so far
From the company's own record
- 23 May 2024Listed on NSE Emerge at ₹97
- 29 Sept 2026Order worth ₹10.71 cr
- 31 March 2026Promoters at 66.78%
- 1 May 2026Highest close since listing, ₹151.65
Quest Laboratories key facts from the filings
Each figure with the document it comes from
- FY26 sales
- ₹111.8 cr
- Revenue from operations, up 7.6% from ₹104.0 cr; profit after tax was ₹14.9 cr, helped by lower tax.Annual report FY26, p.15
- Government business
- 62.5%
- Share of FY25 revenue from government institutions; the rest came from private buyers.Investor presentation, Jul 2025, p.11
- Tablets
- ₹66.7 cr
- FY25 tablet sales, about two thirds of revenue; syrups, suspensions, oral salts and ointments make up the rest.Investor presentation, Jul 2025, p.11
- Tablet capacity used
- 77.9%
- Use of the 360 crore tablets a year capacity in FY25; syrups ran at 87.4% and oral salts at 84.4%.Investor presentation, Jul 2025, p.11
- Order book
- ₹39.7 cr
- Orders in hand on 28 September 2026, including ₹10.7 cr of export orders and ₹16.9 cr of domestic sales booked for the third quarter.Exchange announcement, 28 Sep 2026
Show 5 more facts
- Stock of goods
- ₹38.6 cr
- Inventory at March 2026, up from ₹21.4 cr a year earlier while sales rose less than a tenth.Annual report FY26, p.55
- Money owed by customers
- ₹36.2 cr
- Trade receivables at March 2026, up from ₹30.0 cr.Annual report FY26, p.55
- Short term borrowings
- ₹7.0 cr
- At March 2026, down from ₹28.9 cr, as the company drew down its short term investments to ₹12.2 cr from ₹49.2 cr.Annual report FY26, p.55 and p.56
- Products licensed
- 1,300+
- Formulations the company holds licences for; it makes 250 to 300 of them in a year, depending on demand.Investor presentation, Jul 2025, p.4 and p.16
- Promoter holding
- 66.78%
- Held by the promoter group at March 2026, with none pledged.Shareholding pattern, March 2026
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company told the exchange on 28 September 2026 that it had ₹39.7 cr of orders in hand, with export orders and domestic sales already booked for the third quarter. It says it is building an injectable section with oncology, ampoule, vial and dry injection lines for domestic and export markets, and is registering cardiovascular and diabetes medicines in Myanmar. From FY27 it will report results every half year instead of every quarter.
| What management said | When | What happened |
|---|---|---|
| Domestic sales growth of 30% | Jul 2025 presentation | Total revenue from operations grew 7.6% in FY26 |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Quest Laboratories earns its money making cheap, common medicines in large volumes, mostly for government programmes that hand them out free.
Its weak spots are that tender prices are set by bidding, and a lot of money gets tied up in stock and in what government buyers owe.
WatchCan it set its own prices?Most sales are won in government tenders, where price is a main test, and the company itself names pricing pressure from competition as a risk.
AverageHow strong is it against rivals?It has a wide licensed range and its own testing laboratory, but it makes common generics that many others also make.
WatchWho are its customers?Government health buyers bring most of the money, and sales lean heavily on a few states.
WatchDoes it need a lot of money?Yes for running the business: stock and receivables grew much faster than sales in FY26.
AverageCan it keep finding new work?It has a running order book, a new export business and new lines being built, but growth slowed in FY26.
AverageDo good and bad years swing a lot?Demand for basic medicines is steady, but the timing and size of government tenders can move sales from year to year.
Who runs Quest Laboratories?
Promoters, directors and officers; tap a name for the background
AKAnil Kumar SabarwalPromoter, Chairman and Managing Director
A director since June 1998 with over 25 years in the company; holds a secondary school certificate from Kendriya Vidyalaya, Sriganga Nagar. Responsible for strategy, overall management, new capacity, new products and markets in India and abroad. FY26 pay was ₹0.72 cr.
Offer document, p.179 and p.181; Annual report FY26, p.71TSTejaswini SabarwalPromoter and Whole-Time Director
A Bachelor of Pharmacy from Swami Vivekanand College of Pharmacy, Indore (2017), on the board since March 2021; looks after planning and development of the quality control section. The offer document records Tejaswini Sabarwal and Anil Kumar Sabarwal as husband and wife. FY26 pay was ₹0.30 cr.
Offer document, p.181 and p.182; Annual report FY26, p.71VSVinayak SabarwalWhole-Time Director
A BA in Journalism and Mass Communication from Devi Ahilya University, Indore (2021), studying for a B.Pharm; about three years in various areas of the business. FY26 pay was ₹0.30 cr.
Investor presentation, Jul 2025, p.12; Annual report FY26, p.3 and p.71USUmendra SutharWhole-Time Director
A B.Sc. from Devi Ahilya University, Indore (1991), with over 22 years in pharmaceutical production.
Investor presentation, Jul 2025, p.12; Annual report FY26, p.3 and p.70GKGautam KothariIndependent Director
A fellow chartered accountant with an M.Com, an MA in Sociology and a law degree, and more than 44 years in accounting and finance; also a director of Porwal Auto Components.
Offer document, p.180 and p.181ARAmit Ramesh ChandakIndependent Director
A B.Com from Amravati University and a fellow chartered accountant, with 14 years in taxation, financial reporting, debt syndication and compliance.
Offer document, p.182BLBasant Lal MenghwaniIndependent Director
A Bachelor of Pharmacy from the University of Indore (1977), with around 30 years in the pharmaceutical industry.
Offer document, p.182RSRamkrishna SharmaChief Financial Officer
An MBA in finance from Sikkim Manipal University and a master's in personnel management from Pune University, with 20 years of experience; oversees finance and accounts.
Investor presentation, Jul 2025, p.12ATAyushi TaunkCompany Secretary and Compliance Officer
Appointed from 3 September 2025 after Surabhi Gupta resigned.
Annual report FY26, p.17Quest Laboratories latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹63 cr (+3%), net profit ₹6.9 cr (+24%) on H2 FY25.
- Shareholding, 31 March 2026: promoters unchanged at 66.78%.
- 29 Sept 2026: order worth ₹10.71 cr announced.
Quest Laboratories announcements
80 on record, latest first; each opens the filing on the exchange
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Shareholders meetingvoting results of Annual General Meeting held on September 29, 2025PDF ↗
- Shareholders meetingProceedings of the 28th Annual General MeetingPDF ↗
- Updates'Intimation regarding Strategic Collaboration.'PDF ↗
- Updates'Business Update Order Book Position'PDF ↗
- Updates'Update on Expansion of Manufacturing Facilities'PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Copy of Newspaper PublicationFor Notice of 28th Annual General MeetingPDF ↗
- Outcome of Board MeetingHeld on September 04, 2026, to consider and approve Notice of 28th Annual General MeetingPDF ↗
- Updates'Intimation under Regulation 30 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 Execution of Strategic Growth, Marketing, BusinessDPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Updates': Withdrawal of Trading Window Closure Notice and Re-opening of Trading Window.'PDF ↗
Quest Laboratories annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 31 July 2025 ↗read
- 30 June 2025 ↗read
- 31 Dec 2024 ↗read
Quest Laboratories share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Quest Laboratories' data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,63,87,200 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY21 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Quest Laboratories
What does Quest Laboratories do?
Quest Laboratories makes everyday generic medicines such as tablets, syrups, oral rehydration salts and ointments at its plant in Pithampur, Madhya Pradesh, mostly for government health programmes. Its shares trade on NSE Emerge.
What is the share price of Quest Laboratories?
₹89.1 at the close on 18 Nov 2026, from the exchange's daily figures.
What is the market cap of Quest Laboratories?
₹146 cr at the close on 18 Nov 2026, on 1,63,87,200 shares.
What is the P/E of Quest Laboratories?
9.7 times FY26 profit at the close on 18 Nov 2026 (our arithmetic).
What are Quest Laboratories' revenue and profit?
Revenue ₹112 cr and profit after tax ₹15 cr in FY26.
Who are the promoters of Quest Laboratories?
Anil Kumar Sabarwal, Tejaswini Sabarwal; promoters held 66.78% at 31 March 2026.
What was the IPO price of Quest Laboratories?
₹97 a share; it listed on 23 May 2024.
What is Quest Laboratories' website?
www.questlabltd.com
More SME companies like Quest Laboratories
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Sotac PharmaceuticalsSOTAC · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹143 cr
- Speciality MedicinesSPML · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹136 cr
- Curis LifesciencesCURIS · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹133 cr
- Himalaya Nutravedics IndiaHNIL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹127 cr
- Asston PharmaceuticalsAPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹120 cr
- Bio Medica LaboratoriesBMLL · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹182 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2024 →
Built from 3 investor presentations, 2 annual reports, 1 offer document, 1 result filing, 80 exchange announcements, 7 shareholding patterns and 6 years of reported results. Every figure carries its source; where the documents are silent, the page says so.